Home › Compare › TREVQ vs ABBV
TREVQ yields 2000000.00% · ABBV yields 3.06%● Live data
📍 TREVQ pulled ahead of the other in Year 1
Combined, TREVQ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TREVQ + ABBV for your $10,000?
Trevali Mining Corporation, a base-metals mining company, engages in the acquisition, exploration, development of, and production from mineral properties. It primarily explores for zinc, lead, silver, copper, and gold deposits. The company's operational assets include the 90%-owned Perkoa Mine in Burkina Faso; 90%-owned Rosh Pinah Mine in Namibia; and Caribou Mine in northern New Brunswick, Canada. It also holds interests in the Halfmile, Stratmat, and Restigouche properties situated in New Brunswick, Canada; Gergarub project in Namibia; and Ruttan Mine located in northern Manitoba, Canada. In addition, the company has an option to acquire a 100% interest in the Heath Steele deposit located in New Brunswick, Canada. Trevali Mining Corporation was formerly known as Trevali Resources Corp. and changed its name to Trevali Mining Corporation in April 2011. The company was incorporated in 1964 and is headquartered in Vancouver, Canada.
Full TREVQ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.